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 The first platinum-based drug was discovered and 
approved by Food and Drug Administration (FDA) in 1978 is 
cis-diamminedichloroplatinum (II) (cisplatin or CDDP). 
Cisplatin is used for about 50% of the chemotherapeutic cancer 
treatments along with its two analogues carboplatin and 
oxaliplatin. So far these drugs have been used  extensively as 
treatment for ovarian, bladder, head and neck, and lung cancers. 
Although cisplatin has been used so often, it has toxic side 
effects and drug resistance.1-4 Due to these limitations other 
compounds have been synthesized. Specifically, our lab in 
conjunction with a biochemistry lab has recently published one 
article in this area.5 This project is a continuation to the 
development of anticancer drugs. 
Figure 1. The chemical structures of cisplatin, carboplatin, and 
oxaliplatin. 
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Scheme 2. Synthesis  routes for complex III from 2,2′-bipyridine (A). 
Scheme 3. Synthesis  routes for complex IV from 2,2′-bipyridine (A). 
C24H36Cl2N2O2Pt C% H% Cl% N% O% Pt%
Calc 44.31 5.58 10.90 4.31 4.92 29.99
Found 44.41 6.51 -­‐ 4.37 -­‐ -­‐
Δ 0.1 0.93 -­‐ 0.06 -­‐ -­‐
C34H56Cl2N2O2Pt C% H% Cl% N% O% Pt%
Calc 51.64 7.14 8.97 3.54 4.05 24.67
Found 51.24 7.10 -­‐ 3.80 -­‐ -­‐
Δ 0.4 0.04 -­‐ 0.26 -­‐ -­‐
Figure 4. (a) 1H NMR spectra of ligand 5 (L-C12) and Pt(II)-complex II (Pt-C12) recorded 
in CDCl3 at room temperature. (b) 13C NMR spectra of ligand 5 (L-C12) and Pt(II)-complex 
II (Pt-C12) recorded in CDCl3 at room temperature. 
a) b) 
Figure 5. DSC thermograms of ligand 3 (left) and Pt(II)-complex I (right) obtained 
at heating and cooling rates of 10 °C/min in nitrogen.                 
Figure 6. DSC thermograms of ligand 5 (left) and Pt(II)-complex II (right) 
obtained at heating and cooling rates of 10 °C/min in nitrogen.                 
• This project‘s objective is to synthesize a series of platinum Pt
(II) complexes, I-IV, which will be targeted for testing in 
different cell lines for their therapeutic effects in biochemistry lab 
facilities.  
• The structure-activity relationship will provide a rational basis 
for the discovery of novel platinum compounds with increased 
effectiveness and low toxic side effects. 
b) a) 
•   Platinum complexes I and II were synthesized via a three-step reaction: 
demethylation, SN2 (alkylation), and preparation of the platinum complex by 
coordination chemistry. The products were characterized by using 1H, 13C NMR, 
and elemental analysis.  
•   Unlike small organic compounds, ligands 3 and  5 showed broad melting 
endotherms at 72 and 99 °C, respectively. In contrast, I and II showed multiple 
endotherms in the first heating cycle, but in the second heating cycle they showed 
melting transitions at 174 and 152 °C, respectively.  
•   Ligand E was synthesized by a three-step reaction: oxidation, nitration, and 
reduction. Additionally, ligand D will be synthesized by a three-step synthesis: 
oxidation, nitration, and deoxygenation.    
• All of these platinum complexes will be tested in different cell lines for anticancer 
properties.  
